United States: U.S. Patent Office Releases "May 2016 Subject Matter Eligibility Update"

On May 4, 2016, the United States Patent and Trademark Office ("USPTO") released a "May2016 Subject Matter Eligibility Update" ("May2016 Update"), which provides additional guidance to examiners on patent eligibility under 35U.S.C. § 101, including providing new Life Sciences Examples.

Included in the May 2016 Update are:


The May 2016 Update also provides an open-ended comment period to allow ongoing comments on subject matter eligibility topics and announces the selection of subject matter eligibility rejections as a new case study under the Topic Submission for Case Studies Pilot Program.

The Memorandum

The Memorandum provides examination instructions relating to subject matter eligibility as claimed under § 101.

In particular, the Memorandum addresses: (i) how examiners should formulate a subject matter eligibility rejection under § 101, and (ii) how examiners should evaluate an applicant response to such a rejection. These instructions are intended to assist examiners in applying the 2014 Interim Guidance on Patent Subject Matter Eligibility ("2014 Interim Eligibility Guidance") and the July 2015 Update: Subject Matter Eligibility ("July 2015 Update").

The Memorandum states that examiners should:

  • Identify the judicial exception by referring to what is recited (i.e., set forth or described) in the claim and explain why it is considered an exception;
  • Identify any additional elements (specifically point to claim features/limitations/steps) recited in the claim beyond the identified judicial exception; and
  • Explain the reason(s) that the additional elements taken individually, and also taken as a combination, do not result in the claim as a whole amounting to significantly more than the judicial exception.


The Memorandum also suggests how applicants may effectively respond to a § 101 rejection. In particular, according to the Memorandum, applicants may (i) amend the claim, e.g., to add additional elements or modify existing elements so that the claim as a whole amounts to significantly more than the judicial exception, and/or (ii) present persuasive arguments or evidence based on a good-faith belief as to why the rejection is in error. For example, applicants may challenge the identification of an abstract idea if the original rejection did not identify a U.S. Supreme Court or Federal Circuit decision in which a similar abstract idea was found. Applicants can also present a specific argument or evidence that the additional elements in a claim are not well-understood, routine, conventional activities previously engaged in by those in the relevant art. Further, applicants may argue the claim does not preempt all applications of the judicial exception. But the Memorandum notes that the absence of complete preemption does not demonstrate that a claim is eligible.

Life Sciences Examples

The Life Sciences Examples use hypothetical fact scenarios to illustrate analysis under the 2014 Interim Eligibility Guidance, in view of the Supreme Court decisions in Alice Corp. v. CLS Bank International, 573 U.S. __, 134 S.Ct. 2347, 110 USPQ2d 1976 (2014), Association for Molecular Pathology v. Myriad Genetics, Inc., 569 U.S. __, 133 S. Ct. 2107, 2116, 106 USPQ2d 1972 (2013), and Mayo Collaborative Services v. Prometheus Laboratories, Inc., 566 U.S. __, 132 S. Ct. 1289, 101 USPQ2d 1961 (2012). Under this analysis, if a claim is directed to a judicial exception (e.g., an abstract idea, a law of nature, a product of nature, or a natural phenomenon), then the claim is evaluated to determine if any element, or combination of elements, in the claim is sufficient to ensure that the claim amounts to "significantly more" than the judicial exception.

The original Nature-Based Products Examples in the 2014 Interim Eligibility Guidance included 10 natural product examples (gunpowder and fireworks; pomelo juice; amazonic acid, pharmaceutical compositions, and methods of treatment; purified proteins; genetically modified bacterium; bacterial mixtures; nucleic acids; antibodies; cells; and food).

The new Life Sciences Examples in the May2016 Update include:

  • Two new natural product examples (vaccines and dietary sweeteners);
  • One new law of nature example (diagnosing and treating a disease);
  • One new abstract idea example (screening for gene alterations); and
  • Two new streamlined analysis examples (paper-making machine and fat hydrolysis).


Two of these examples are highlighted below.

Example 28: Vaccines. New example 28 "Vaccines" illustrates the application of the markedly different characteristics and significantly more analyses to claims reciting hypothetical nature-based products.

In this example, the hypothetical patent applicant filed an application disclosing several types of Pigeon flu vaccines and evaluating their functional characteristics, such as immunogenicity.

Seven exemplary claims are provided by the USPTO. Four of these claims are reproduced below:

  1. A vaccine comprising live attenuated Pigeon flu virus.
  2. A vaccine comprising inactivated Pigeon flu virus.
  3. A vaccine comprising: Peptide F; and a pharmaceutically acceptable carrier.
  4. A vaccine comprising: Peptide F; and a pharmaceutically acceptable carrier selected from the group consisting of a cream, emulsion, gel, liposome, nanoparticle, or ointment.


The example notes that the specification defines "live attenuated Pigeon flu virus" as a live mutant virus that has been attenuated so that it has at least one mutation of its polymerase gene, which reduces its virulence as compared to naturally occurring Pigeon flu virus. No mutations of this polymerase gene are known to occur in nature.

The example also notes that the specification defines "inactivated Pigeon flu virus" as a naturally occurring Pigeon flu virus that has been contacted with the chemical formalin that causes structural changes to the virus so that it can no longer reproduce.

The example further notes that prior to applicant's invention, water was routinely and conventionally used as a carrier for peptide vaccines. Isolation does not change any structural or functional characteristics of Peptide F (a naturally occurring peptide isolated from the Pigeon flu virus). The example also notes that although a pharmaceutically acceptable carrier, selected from a group consisting of a cream, emulsion, gel, liposome, nanoparticle, or ointment, comprises naturally occurring components (such as water and oil), when the components are assembled into the carrier form, the carrier has changed structural and physical characteristics that distinguish it from the closest counterpart in nature.

Claim 1 recites a vaccine comprising live attenuated Pigeon flu virus. Claim 2 recites a vaccine comprising inactivated Pigeon flu virus. Because both the live attenuated virus and the inactivated virus have markedly different characteristics from what exists in nature, these claims are not directed to a "product of nature" exception. Thus, both claims 1 and 2 are subject matter eligible.

Claims 3 and 4 both recite a mixture of Peptide F and a pharmaceutically acceptable carrier. In the case of claim 3, the carrier may be water, whereas for claim 4, the carrier is specified as a cream, emulsion, gel, liposome, nanoparticle, or ointment. As such, these claims are directed to a nature-based product that must be compared to its closest naturally occurring counterpart to determine if it has markedly different characteristics than the counterpart. For claim 3, there is no indication that mixing a peptide and water changes the structure, function, or other properties of the peptide or water. Thus, claim 3 is not subject matter eligible. In contrast, for claim 4, the recited carrier changes structural and physical characteristics that distinguish it from the closest counterpart in nature. Thus, claim 4 is subject matter eligible.

Example 29: Diagnosing and Treating Julitis. New example 29 "diagnosing and treating julitis" illustrates the application of the significantly more analysis to diagnostic and treatment claims using a hypothetical disease (julitis).

The hypothetical patent applicant discovered the presence of a protein known as "JUL-1" in a patient that can be used as a marker for the disease. The application discloses detection of the marker "JUL-1" by routine and conventional methods such as by immunoassays.

Seven exemplary claims are provided by the USPTO, and they are reproduced below:

1. A method of detecting JUL-1 in a patient, said method comprising:

  • obtaining a plasma sample from a human patient; and
  • detecting whether JUL-1 is present in the plasma sample by contacting the plasma sample with an anti-JUL-1 antibody and detecting binding between JUL-1 and the antibody.


2. A method of diagnosing julitis in a patient, said method comprising:

  • obtaining a plasma sample from a human patient;
  • detecting whether JUL-1 is present in the plasma sample by contacting the plasma sample with an anti-JUL-1 antibody and detecting binding between JUL-1 and the antibody; and
  • diagnosing the patient with julitis when the presence of JUL-1 in the plasma sample is detected.


3. A method of diagnosing julitis in a patient, said method comprising:

  • obtaining a plasma sample from a human patient;
  • detecting whether JUL-1 is present in the plasma sample by contacting the plasma sample with a porcine anti-JUL-1 antibody and detecting binding between JUL-1 and the porcine antibody; and
  • diagnosing the patient with julitis when the presence of JUL-1 in the plasma sample is detected.


4. A method of diagnosing julitis in a patient, said method comprising:

  • obtaining a plasma sample from a human patient;
  • detecting whether JUL-1 is present in the plasma sample by contacting the plasma sample with antibody mAb-D33 and detecting binding between JUL-1 and antibody mAb-D33; and
  • diagnosing the patient with julitis when the presence of JUL-1 in the plasma sample is detected.


5. A method of diagnosing and treating julitis in a patient, said method comprising:

  • obtaining a plasma sample from a human patient;
  • detecting whether JUL-1 is present in the plasma sample;
  • diagnosing the patient with julitis when the presence of JUL-1 in the plasma sample is detected; and
  • administering an effective amount of topical vitamin D to the diagnosed patient.


6. A method of diagnosing and treating julitis in a patient, said method comprising:

  • obtaining a plasma sample from a human patient;
  • detecting whether JUL-1 is present in the plasma sample;
  • diagnosing the patient with julitis when the presence of JUL-1 in the plasma sample is detected; and
  • administering an effective amount of anti-tumor necrosis factor ("TNF") antibodies to the diagnosed patient.


7.Amethod of treating a patient with julitis, the method comprising administering an effective amount of anti-TNF antibodies to a patient suffering from julitis.

The example notes that applicant discloses detecting JUL-1 using anti-JUL-1 antibodies that may be naturally occurring (e.g., a human anti-JUL-1 antibody isolated from a patient known to have julitis), or non-naturally occurring (e.g., a porcine anti-JUL-1 antibody created by injecting pigs with JUL-1, or a specific monoclonal antibody named "mAb-D33" that was created by applicant). The example also notes that prior to applicant's invention, the use of porcine antibodies in veterinary therapeutics was known to most scientists in the field, but these antibodies were not routinely or conventionally used to detect human proteins such as JUL-1.

The example further notes that prior to applicant's invention, julitis was conventionally treated with anti-TNF antibodies, but for unknown reasons, some patients did not respond well to this conventional treatment. Applicant has successfully treated julitis patients (even those who are non-responsive to anti-TNF antibodies) with topical vitamin D, which had not previously been used to treat julitis.

Claim 1 recites two steps, obtaining a sample and detecting the presence of JUL-1 using an antibody. Because this claim is not directed to an exception, it is subject matter eligible. Compare with Ariosa Diagnostics, Inc. v. Sequenom, Inc., 788 F.3d 1371 (Fed. Cir. 2015).

Claim 2 adds a third diagnosing step that "describes a correlation or relationship between the presence of JUL-1 in a patient's plasma and the presence of julitis in the patient," and thus, according to the USPTO, is directed to a judicial exception. The first two steps (recited in claim1) are found to be conventional and routine and do not add something beyond the judicial exception. Thus, this claim is not subject matter eligible.

Claim 3 is also directed to a judicial exception because it recites a third diagnosing step. However, the use of the porcine antibody (which was not routinely used to detect human JUL-1 protein) adds an unconventional step such that the claim amounts to "significantly more" than the exception. Thus, this claim is subject matter eligible.

Similarly, claim 4 requires the use of the antibody mAb-D33 (which was not routinely used to detect human JUL-1 protein). Thus, this claim is also subject matter eligible.

Claims 5–7 recite nature-based product limitations (vitamin D, anti-TNF antibodies) but also recite administering steps, which are found to add "something more" to the claims. Thus, these claims are subject matter eligible.

Conclusion

The May 2016 Update provides additional guidance for examiners and applicants on how to formulate, understand, and respond to § 101 rejections, and it provides additional specific eligibility examples for those in the life sciences field, including for claims to vaccines and claims to methods of diagnosis or treatment.

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

To print this article, all you need is to be registered on Mondaq.com.

Click to Login as an existing user or Register so you can print this article.

Authors
 
In association with
Related Video
Up-coming Events Search
Tools
Print
Font Size:
Translation
Channels
Mondaq on Twitter
 
Register for Access and our Free Biweekly Alert for
This service is completely free. Access 250,000 archived articles from 100+ countries and get a personalised email twice a week covering developments (and yes, our lawyers like to think you’ve read our Disclaimer).
 
Email Address
Company Name
Password
Confirm Password
Position
Mondaq Topics -- Select your Interests
 Accounting
 Anti-trust
 Commercial
 Compliance
 Consumer
 Criminal
 Employment
 Energy
 Environment
 Family
 Finance
 Government
 Healthcare
 Immigration
 Insolvency
 Insurance
 International
 IP
 Law Performance
 Law Practice
 Litigation
 Media & IT
 Privacy
 Real Estate
 Strategy
 Tax
 Technology
 Transport
 Wealth Mgt
Regions
Africa
Asia
Asia Pacific
Australasia
Canada
Caribbean
Europe
European Union
Latin America
Middle East
U.K.
United States
Worldwide Updates
Check to state you have read and
agree to our Terms and Conditions

Terms & Conditions and Privacy Statement

Mondaq.com (the Website) is owned and managed by Mondaq Ltd and as a user you are granted a non-exclusive, revocable license to access the Website under its terms and conditions of use. Your use of the Website constitutes your agreement to the following terms and conditions of use. Mondaq Ltd may terminate your use of the Website if you are in breach of these terms and conditions or if Mondaq Ltd decides to terminate your license of use for whatever reason.

Use of www.mondaq.com

You may use the Website but are required to register as a user if you wish to read the full text of the content and articles available (the Content). You may not modify, publish, transmit, transfer or sell, reproduce, create derivative works from, distribute, perform, link, display, or in any way exploit any of the Content, in whole or in part, except as expressly permitted in these terms & conditions or with the prior written consent of Mondaq Ltd. You may not use electronic or other means to extract details or information about Mondaq.com’s content, users or contributors in order to offer them any services or products which compete directly or indirectly with Mondaq Ltd’s services and products.

Disclaimer

Mondaq Ltd and/or its respective suppliers make no representations about the suitability of the information contained in the documents and related graphics published on this server for any purpose. All such documents and related graphics are provided "as is" without warranty of any kind. Mondaq Ltd and/or its respective suppliers hereby disclaim all warranties and conditions with regard to this information, including all implied warranties and conditions of merchantability, fitness for a particular purpose, title and non-infringement. In no event shall Mondaq Ltd and/or its respective suppliers be liable for any special, indirect or consequential damages or any damages whatsoever resulting from loss of use, data or profits, whether in an action of contract, negligence or other tortious action, arising out of or in connection with the use or performance of information available from this server.

The documents and related graphics published on this server could include technical inaccuracies or typographical errors. Changes are periodically added to the information herein. Mondaq Ltd and/or its respective suppliers may make improvements and/or changes in the product(s) and/or the program(s) described herein at any time.

Registration

Mondaq Ltd requires you to register and provide information that personally identifies you, including what sort of information you are interested in, for three primary purposes:

  • To allow you to personalize the Mondaq websites you are visiting.
  • To enable features such as password reminder, newsletter alerts, email a colleague, and linking from Mondaq (and its affiliate sites) to your website.
  • To produce demographic feedback for our information providers who provide information free for your use.

Mondaq (and its affiliate sites) do not sell or provide your details to third parties other than information providers. The reason we provide our information providers with this information is so that they can measure the response their articles are receiving and provide you with information about their products and services.

If you do not want us to provide your name and email address you may opt out by clicking here .

If you do not wish to receive any future announcements of products and services offered by Mondaq by clicking here .

Information Collection and Use

We require site users to register with Mondaq (and its affiliate sites) to view the free information on the site. We also collect information from our users at several different points on the websites: this is so that we can customise the sites according to individual usage, provide 'session-aware' functionality, and ensure that content is acquired and developed appropriately. This gives us an overall picture of our user profiles, which in turn shows to our Editorial Contributors the type of person they are reaching by posting articles on Mondaq (and its affiliate sites) – meaning more free content for registered users.

We are only able to provide the material on the Mondaq (and its affiliate sites) site free to site visitors because we can pass on information about the pages that users are viewing and the personal information users provide to us (e.g. email addresses) to reputable contributing firms such as law firms who author those pages. We do not sell or rent information to anyone else other than the authors of those pages, who may change from time to time. Should you wish us not to disclose your details to any of these parties, please tick the box above or tick the box marked "Opt out of Registration Information Disclosure" on the Your Profile page. We and our author organisations may only contact you via email or other means if you allow us to do so. Users can opt out of contact when they register on the site, or send an email to unsubscribe@mondaq.com with “no disclosure” in the subject heading

Mondaq News Alerts

In order to receive Mondaq News Alerts, users have to complete a separate registration form. This is a personalised service where users choose regions and topics of interest and we send it only to those users who have requested it. Users can stop receiving these Alerts by going to the Mondaq News Alerts page and deselecting all interest areas. In the same way users can amend their personal preferences to add or remove subject areas.

Cookies

A cookie is a small text file written to a user’s hard drive that contains an identifying user number. The cookies do not contain any personal information about users. We use the cookie so users do not have to log in every time they use the service and the cookie will automatically expire if you do not visit the Mondaq website (or its affiliate sites) for 12 months. We also use the cookie to personalise a user's experience of the site (for example to show information specific to a user's region). As the Mondaq sites are fully personalised and cookies are essential to its core technology the site will function unpredictably with browsers that do not support cookies - or where cookies are disabled (in these circumstances we advise you to attempt to locate the information you require elsewhere on the web). However if you are concerned about the presence of a Mondaq cookie on your machine you can also choose to expire the cookie immediately (remove it) by selecting the 'Log Off' menu option as the last thing you do when you use the site.

Some of our business partners may use cookies on our site (for example, advertisers). However, we have no access to or control over these cookies and we are not aware of any at present that do so.

Log Files

We use IP addresses to analyse trends, administer the site, track movement, and gather broad demographic information for aggregate use. IP addresses are not linked to personally identifiable information.

Links

This web site contains links to other sites. Please be aware that Mondaq (or its affiliate sites) are not responsible for the privacy practices of such other sites. We encourage our users to be aware when they leave our site and to read the privacy statements of these third party sites. This privacy statement applies solely to information collected by this Web site.

Surveys & Contests

From time-to-time our site requests information from users via surveys or contests. Participation in these surveys or contests is completely voluntary and the user therefore has a choice whether or not to disclose any information requested. Information requested may include contact information (such as name and delivery address), and demographic information (such as postcode, age level). Contact information will be used to notify the winners and award prizes. Survey information will be used for purposes of monitoring or improving the functionality of the site.

Mail-A-Friend

If a user elects to use our referral service for informing a friend about our site, we ask them for the friend’s name and email address. Mondaq stores this information and may contact the friend to invite them to register with Mondaq, but they will not be contacted more than once. The friend may contact Mondaq to request the removal of this information from our database.

Security

This website takes every reasonable precaution to protect our users’ information. When users submit sensitive information via the website, your information is protected using firewalls and other security technology. If you have any questions about the security at our website, you can send an email to webmaster@mondaq.com.

Correcting/Updating Personal Information

If a user’s personally identifiable information changes (such as postcode), or if a user no longer desires our service, we will endeavour to provide a way to correct, update or remove that user’s personal data provided to us. This can usually be done at the “Your Profile” page or by sending an email to EditorialAdvisor@mondaq.com.

Notification of Changes

If we decide to change our Terms & Conditions or Privacy Policy, we will post those changes on our site so our users are always aware of what information we collect, how we use it, and under what circumstances, if any, we disclose it. If at any point we decide to use personally identifiable information in a manner different from that stated at the time it was collected, we will notify users by way of an email. Users will have a choice as to whether or not we use their information in this different manner. We will use information in accordance with the privacy policy under which the information was collected.

How to contact Mondaq

You can contact us with comments or queries at enquiries@mondaq.com.

If for some reason you believe Mondaq Ltd. has not adhered to these principles, please notify us by e-mail at problems@mondaq.com and we will use commercially reasonable efforts to determine and correct the problem promptly.